PREDICTIVE BIOMARKER OF SURVIVAL IN THE TREATMENT OF RENAL CELL CARCINOMA

摘要

Methods and compositions are disclosed for predicting and treating the clinical benefit to a human renal cell carcinoma patient prior to their treatment with a VEGFR inhibitor and an Ang2 inhibitor.

主权项

1. A method of predicting human renal cell carcinoma (RCC) patients having an increased likelihood of obtaining clinical benefit from, and prior to treatment with, a therapeutically effective amount of a VEGFR inhibitor and an Ang2 inhibitor, the method comprising comparing a patient PLGF concentration with a PLGF concentration parameter, wherein the patient PLGF concentration lower than the PLGF concentration parameter is predictive of the increased likelihood of clinical benefit.